Table 2 Patient demographics of the cohort that was prospectively studied for the neurologist’s perceived usefulness of biomarker sNfL
Total | |
|---|---|
n | 109 |
Age, mean (SD) | 63 (9) |
Sex = f, n (%) | 44 (40) |
MMSE, median [IQR] | 26 [23, 28] |
CSF biomarkers available = Y (%) | 76 (69) |
Doubt diagnosis = yes (%) | 18 (17) |
Diagnosis, n (%) | |
Subjective cognitive decline (SCD) | 28 (26) |
Mild cognitive impairment (MCI), of which 3 due to AD, 2 clinically defined | 5 (5) |
Dementia due to AD | 29 (27) |
Other dementia (OD) | 11 (10) |
Other neurology (ON) | 11 (10) |
Psychiatric disorder | 17 (16) |
Postponed | 8 (7) |
aβ1-42, pg/mL (median [IQR]) | 889 [559, 1446] |
pTau, pg/mL (median [IQR]) | 16 [11, 26] |
tTAU, pg/mL (median [IQR]) | 200 [135, 290] |
sNfL, pg/mL (median [IQR]) | 14 [10, 19] |